In re Terazosin Hydrochloride Antitrust Litigation
Case No. 99-MDL-1317 (S.D. Fla.) (Hon. Patricia A. Seitz)


Plaintiffs allege defendants, pharmaceutical manufacturers and marketers, engaged in a conspiracy in violation of federal antitrust laws to restrain trade by keeping generic competition out of the market for Hytrin. To date, Judge Seitz, after intensive briefing and oral argument, has found a per se violation of Section 1 of the Sherman Act (2000 WL33534279 (S.D. Fla., 2000)) and has recently certified a class of direct purchasers. (2001 WL 1160789 (S.D. Fla, 2001)).

Garwin, Bronzaft, Gerstein & Fisher, L.L.P. is co-lead counsel in this case.

On April 15, 2005, the United States District Court for the Southern District of Florida finally approved a $75 million dollar settlement of this antitrust suit for the benefit of a class of direct purchasers of the brand-name hypertension drug Hytrin. The complaint alleged that Abbott, Zenith Pharms. Inc. (now known as Ivax Pharms., Inc.) and Geneva Pharms. Inc., collectively violated Section 1 of the Sherman Act by entering into an illegal agreement which improperly delayed competition from generic versions of Hytrin, thereby causing direct purchasers of the brand name drug to overpay for the drug.

View the current settlement documents

SETTLEMENT AGREEMENT

NOTICE OF PROPOSED PARTIAL SETTLEMENT AND HEARING REGARDING SETTLEMENT